Passage Bio/$PASG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Passage Bio
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
Ticker
$PASG
Sector
Primary listing
Employees
24
Headquarters
Website
Passage Bio Metrics
BasicAdvanced
$20M
-
-$14.35
1.77
-
Price and volume
Market cap
$20M
Beta
1.77
52-week high
$20.00
52-week low
$5.12
Average daily volume
35K
Financial strength
Current ratio
2.069
Quick ratio
2.006
Long term debt to equity
109
Total debt to equity
128.019
Profitability
EBITDA (TTM)
-42.423
Management effectiveness
Return on assets (TTM)
-32.75%
Return on equity (TTM)
-113.78%
Valuation
Price to book
1.05
Price to tangible book (TTM)
1.05
Price to free cash flow (TTM)
-0.622
Free cash flow yield (TTM)
-160.69%
Free cash flow per share (TTM)
-9.931
Growth
Earnings per share change (TTM)
-31.80%
3-year earnings per share growth (CAGR)
-34.05%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Passage Bio stock?
Passage Bio (PASG) has a market cap of $20M as of March 31, 2026.
What is the P/E ratio for Passage Bio stock?
The price to earnings (P/E) ratio for Passage Bio (PASG) stock is 0 as of March 31, 2026.
Does Passage Bio stock pay dividends?
No, Passage Bio (PASG) stock does not pay dividends to its shareholders as of March 31, 2026.
When is the next Passage Bio dividend payment date?
Passage Bio (PASG) stock does not pay dividends to its shareholders.
What is the beta indicator for Passage Bio?
Passage Bio (PASG) has a beta rating of 1.77. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.